Want to see RMTG full AI Analyst Report?
RMTG Stock Chart & Stats
$0.10
>-$0.01(-26.32%)
At close: 4:00 PM EST
$0.10
>-$0.01(-26.32%)
Day’s Range― - ―
52-Week Range$0.02 - $0.13
Previous CloseN/A
Volume89.42K
Average Volume (3M)67.32K
Market Cap
$790.64K
Enterprise Value$21.03
Total Cash (Recent Filing)$1.32M
Total Debt (Recent Filing)$21.74M
Price to Earnings (P/E)―
Beta-2.15
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,738,968
10 Day Avg. Volume58,719
30 Day Avg. Volume67,317
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.02
Price to Sales (P/S)0.12
P/FCF Ratio-0.47
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSharp revenue expansion demonstrates growing demand for the company’s regenerative medicine offerings and broader commercial reach. If sustained, this scale can improve operating leverage, support investment in higher-margin products, and strengthen the platform’s competitive position over the next several quarters.
Solid Gross Economics And Improving OperationsA nearly 60% gross margin provides a meaningful economic base from which the company can fund growth and improve profitability. The move to slightly positive EBIT suggests operating performance is improving, although substantial below-the-line costs still prevent the benefit from reaching net income.
Strategy To Build Recurring, Higher-margin RevenueExpanding recurring education and affiliate revenue could make the business less dependent on individual product sales and improve revenue visibility. A larger doctor-training network may also reinforce distribution, customer engagement, and demand for associated products as the platform develops.
Bears Say
Stressed Capital StructureNegative equity and debt that is large relative to the asset base indicate limited balance-sheet cushion for creditors and shareholders. This reduces financial flexibility, makes deleveraging important, and can constrain the company’s ability to fund expansion without additional capital or restructuring.
Persistent Substantial Net LossesLarge net losses show that gross profit is currently overwhelmed by overhead, research and development, and other costs or non-operating items. Continued losses can erode capital, delay self-sustaining profitability, and make successful execution of the growth strategy more financially demanding.
Negative Free Cash Flow And Financing DependenceNegative free cash flow means operations are not yet generating enough cash after capital spending to fund growth internally. Combined with rising interest expense and significant liabilities, this increases reliance on external financing and leaves less flexibility if expansion takes longer to generate returns.
Regenerative Medical Technology Group News
RMTG FAQ
What was Regenerative Medical Technology Group’s price range in the past 12 months?
Regenerative Medical Technology Group lowest stock price was $0.02 and its highest was $0.13 in the past 12 months.
What is Regenerative Medical Technology Group’s market cap?
Regenerative Medical Technology Group’s market cap is $790.64K.
When is Regenerative Medical Technology Group’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Regenerative Medical Technology Group’s earnings last quarter?
Currently, no data Available
Is Regenerative Medical Technology Group overvalued?
According to Wall Street analysts Regenerative Medical Technology Group’s price is currently Overvalued.
Does Regenerative Medical Technology Group pay dividends?
Regenerative Medical Technology Group does not currently pay dividends.
What is Regenerative Medical Technology Group’s EPS estimate?
Regenerative Medical Technology Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regenerative Medical Technology Group have?
Regenerative Medical Technology Group has 13,738,968 shares outstanding.
What happened to Regenerative Medical Technology Group’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Regenerative Medical Technology Group?
Currently, no hedge funds are holding shares in RMTG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Regenerative Medical Technology Group
Regenerative Medical Technology Group Inc. operates in the regenerative medicine industry in the United States and internationally. It provides products, solutions, equipment, services, and training to doctors and their staff in the application of stem cell therapies. The company is also involved in the treatment of patients; provision of training and seminars; and resale of kits, products, equipment, and services. In addition, it offers reoccurring application of its process using its kits and solutions. The company was formerly known as Meso Numismatics, Inc. and changed its name to Regenerative Medical Technology Group Inc. in May 2024. Regenerative Medical Technology Group Inc. was incorporated in 1999 and is based in Boca Raton, Florida.
Technical Analysis
Bone Biologics
―
INVO Fertility
―
Bluejay Diagnostics
―
NewGenIvf Group
―
WORK Medical Technology Group LTD
―